𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Value of imaging techniques in the differentiation between benign and malignant kidney lesions

✍ Scribed by Navajas, Aurora; Vita, Maria Jes�s


Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
88 KB
Volume
32
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Delayed 18F-fluoro-2-deoxy-D-glucose pos
✍ Yuji Nakamoto; Tatsuya Higashi; Harumi Sakahara; Nagara Tamaki; Masafumi Kogire; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 331 KB 👁 1 views

## Background: Positron emission tomography (pet) using (18)f-fluoro-2-deoxy-d-glucose (fdg) has been used for the evaluation of various tumors, but accumulation in inflammatory lesions makes it a controversial modality. the aim of this study was to investigate the usefulness of delayed scanning in

Evaluation of DNA ploidy and degree of D
✍ Henryk Pilch; Susanne Günzel; Uwe Schäffer; Berno Tanner; Michael Heine 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB 👁 2 views

## BACKGROUND. Making a morphologic distinction between benign and malignant melanocytic tumors of the skin is frequently difficult, especially because "gray zones" between these lesions often exist. DNA image cytometry as an adjuvant method for the diagnosis and prognostic prediction of premaligna

Combined laparoscopic and flexible endos
✍ Morris E. Franklin Jr.; Daniel Abrego; Jorge Balli 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 1 views

Most malignancies of the gastrointestinal tract rise from intraluminal sources. Endoscopic evaluation for diagnosis and treatment of these disease processes is a very accurate and inexpensive method compared with non-endoscopic methods alone. Combined laparoscopic and flexible endoscopic techniques

Immunohistochemical staining for DNA top
✍ Willman, Joseph H.; Holden, Joseph A. 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 455 KB 👁 2 views

## BACKGROUND. The DNA topoisomerase II-alpha (topo II-alpha)-targeting drug etoposide was recently shown to be an active agent in the combined chemotherapy of hormoneinsensitive prostatic carcinoma. Aside from being the molecular target of etoposide, topo II-alpha is also a cell proliferation mark